Phio Pharmaceuticals
PHIO
6 hedge funds and large institutions have $98.3K invested in Phio Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 7 closing their positions.
2.91% more ownership
Funds ownership: 0.41% → 3.31% (+2.9%)
16% less capital invested
Capital invested by funds: $117K → $98.3K (-$18.6K)
45% less funds holding
Funds holding: 11 → 6 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$90.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.07K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.93K |
| 4 |
NA
Nordwand Advisors
Radnor,
Pennsylvania
|
+$1.79K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$24.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$19.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.9K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$16.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $86.7K | +$90.1K | +25,131 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $5.81K | +$5.07K | +1,413 | +519% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $4.05K | +$1.93K | +537 | +84% |
|
|
NA
4
Nordwand Advisors
Radnor,
Pennsylvania
| $1.73K | +$1.79K | +500 | New |
|
|
AWM
5
Activest Wealth Management
Aventure,
Florida
| $31 | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| $24 | +$11 | +3 | +75% |
|
|
7
Cetera Investment Advisers
Schaumburg,
Illinois
| – | -$24.5K | -3,935 | Closed |
|
|
8
Geode Capital Management
Boston,
Massachusetts
| – | -$19.7K | -3,126 | Closed |
|
|
9
Vanguard Group
Malvern,
Pennsylvania
| – | -$16.9K | -2,709 | Closed |
|
|
BCM
10
Bridgeway Capital Management
Houston,
Texas
| – | -$16.4K | -2,610 | Closed |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$15.2K | -2,410 | Closed |
|
12
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$10K | -1,581 | Closed |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$8.62K | -1,384 | Closed |
|
14
BlackRock
New York
| – | -$1 | – | – |
|
PHIO Hedge Fund Activity: Q3 2024 in Review
6 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2024, worth a combined $98.3K — down 16% from $117K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PHIO and 2 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $90.1K. The largest seller was Cetera Investment Advisers, exiting entirely with an estimated $24.5K sold.
- 6 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2024, down from 11 in Q2 2024.
- Funds reported $98.3K of Phio Pharmaceuticals stock for Q3 2024, down 16% quarter-over-quarter.
- 2 funds opened new Phio Pharmaceuticals positions in Q3 2024 and 7 closed out, a net change of -5 holders.
- The largest Phio Pharmaceuticals buyer in Q3 2024 was Sabby Management, an estimated $90.1K added.
- The largest Phio Pharmaceuticals seller in Q3 2024 was Cetera Investment Advisers, an estimated $24.5K sold.
Based on aggregated 13F filings for Q3 2024.